SCHEMBL2862774

SCHEMBL2862774

COc1cc2c(Oc3ccc(N4C(=O)NC(C)C4=O)cc3F)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 3/20 0.68
MET P08581 16/20 0.60
FLT3 P36888 3/20 0.59
KDR P35968 4/20 0.58
MST1R Q04912 4/20 0.58
EGFR P00533 3/20 0.58
RPS6KB1 P23443 3/20 0.58
FLT4 P35916 3/20 0.58
TEK Q02763 3/20 0.58
BTK Q06187 3/20 0.58
AURKA O14965 2/20 0.58
LCK P06239 2/20 0.58
CSF1R P07333 2/20 0.58
JAK2 O60674 2/20 0.58
FLT1 P17948 2/20 0.58
FGFR2 P21802 2/20 0.58
PLK4 O00444 1/20 0.58
STK25 O00506 1/20 0.58
CIT O14578 1/20 0.58
CHUK O15111 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13511883 1.00 AXL (0.68) AXLMETFLT3KDRMST1R
SCHEMBL2856001 0.90 AXL (0.65) AXLMETFLT3KDRMST1R
SCHEMBL2861187 0.90 AXL (0.65) AXLMETFLT3KDRMST1R
SCHEMBL2866089 0.88 MET (0.63) AXLMETFLT3KDRMST1R
SCHEMBL13513817 0.88 AXL (0.61) AXLMETFLT3KDRMST1R
SCHEMBL5223356 0.87 MET (0.61) AXLMETFLT3KDRMST1R
SCHEMBL2855812 0.85 AXL (0.74) AXLMETFLT3KDRMST1R
SCHEMBL2868384 0.83 AXL (0.69) AXLMETFLT3KDRMST1R
SCHEMBL13511878 0.83 AXL (0.73) AXLMETFLT3KDRMST1R
SCHEMBL2864821 0.83 AXL (0.62) AXLMETFLT3KDRMST1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1827434-B1 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER AMGEN INC (US) 2014-01-15 EP claimed
US-20060252777-A1 Substituted heterocycles and methods of use AMGEN INC. (US) 2006-11-09 US claimed
EP-1827434-B1 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER AMGEN INC (US) 2014-01-15 EP disclosed
US-7652009-B2 Substituted heterocycles and methods of use AMGEM INC. (US) 2010-01-26 US disclosed
EP-1827434-A2 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER Amgen Inc. (US) 2007-09-05 EP disclosed
US-20060252777-A1 Substituted heterocycles and methods of use AMGEN INC. (US) 2006-11-09 US disclosed
WO-2006060318-A2 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER AMGEN INC. (US) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252777-A1 Substituted heterocycles and methods of use HGF, HGFAC, MET AXL 578/4885MET 3/4885FLT3 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.